Mission plko 1 puro control vector

BEAS2B (normal human bronchial epithelial cell line) and HEK293T (human embryonic kidney cell line) cells were commercially obtained (ATCC, Manassas, VA, USA). BEAS2B cells were cultured in Bronchial/Trachea Epithelial Cell Growth Medium, and HEK293T cells were cultured in the Dulbecco’s Modified Eagle’s medium supplemented with 10% fetal bovine serum, 50 U/mL penicillin-streptomycin, and 25 ug/mL gentamicin.
ShRNA-based knockdown studies were conceived and carried out strictly in accordance with previously published protocol [33 (link)]. All shRNA constructs, including the MISSION^® pLKO.1-puro control vector, MISSION^® Non-Target shRNA (shNT), and shRNAs targeting Prx4 (shPrx4) or Srx (shSrx), were obtained commercially from Sigma Aldrich. Lentiviral particles expressing shRNAs were created in HEK293T cells in accordance with the manufacturer’s recommended transfection and virus production protocols. A549 cells were infected with lentiviral particles containing either control shNT or shRNA targeting the coding region of Prx4 or Srx and maintained in the puromycin-containing medium (1.0 µg/mL).